American Journal of Cardiology
Volume 99, Issue 9 , Pages 1212-1215 , 1 May 2007

Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)

  • Benjamin A. Steinberg, BA

      Affiliations

    • Thrombolysis In Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • P. Gabriel Steg, MD

      Affiliations

    • Hôpital Bichat-Claude Bernard, Services de Cardiologie, Pairs, France
    • Dr. Steg has received honoraria for consulting or lectures from AstraZeneca, Bristol-Myers Squibb, Merck-Sharp Dohme, Nycomed, GlaxoSmithKline, Nycomed, Sanofi-Aventis, Servier, Takeda. His department has received a research grant from Sanofi-Aventis.
    • ,
  • Deepak L. Bhatt, MD

      Affiliations

    • Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio
    • Dr. Bhatt has received honoraria for consulting on scientific advisory boards from AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi-Aventis, Schering Plough, The Medicines Company and honoraria for lectures from Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company.
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • David Geffen School of Medicine, UCLA, Los Angeles, California
    • Dr. Fonarow has received research grants from GlaxoSmithKline, Pfizer, and Amgen. He is on the speaker’s bureau or has received honoraria from Sanofi-Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck, Schering-Plough, AstraZeneca, Amgen, and Biosite. He is a consultant for Sanofi-Aventis, GlaxoSmithKline, Pfizer, Merck, Schering Plough, and Bristol-Myers Squibb.
    • ,
  • Uwe Zeymer, MD

      Affiliations

    • Herzzentrum Ludwigshafen, Medizinische Klinik II, Ludwigshafen, Germany.
    • Dr. Zeymer has received research grants and honoraria for speaker bureau meetings from Bristol Myers Squibb, Sanofi Aventis, and Boehringer Ingelheim.
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Thrombolysis In Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
    • Dr. Cannon has received research grant support from Merck, AstraZeneca, Schering-Plough, and Accumetrics. He serves on advisory boards as a consultant with AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Schering-Plough, Pfizer, and Sanofi-Aventis.
    • Corresponding Author InformationCorresponding author: Tel: 617-278-0146; fax: 617-734-7329.
    • ,
  • REACH Registry Investigators

      Affiliations

    • The REACH Registry is sponsored by Sanofi-Aventis, Paris, France; Bristol-Myers Squibb, New York, New York; and the Waksman Foundation, Tokyo, Japan.

Received 2 November 2006 ,Revised 7 December 2006 ,Accepted 7 December 2006.

References 

  1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110(suppl):e82–e292
  3. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151(suppl):e1–e10
  4. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  5. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–2139
  6. Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart. 2002;88:159–162
  7. Steg PG, Iung B, Feldman LJ, Cokkinos D, Deckers J, Fox KA, et al. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart. 2002;88:20–24
  8. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006;151:185–191
  9. Mehilli J, Kastrati A, Dirschinger J, Pache J, Seyfarth M, Blasini R, et al. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. JAMA. 2002;287:210–215
  10. Mueller C, Neumann FJ, Roskamm H, Buser P, Hodgson JM, Perruchoud AP, et al. Women do have an improved long-term outcome after non–ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients. J Am Coll Cardiol. 2002;40:245–250
  11. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288:3124–3129
  12. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E Writing Group. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2468–2482
  13. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373–377

PII: S0002-9149(07)00150-6

doi: 10.1016/j.amjcard.2006.12.039

American Journal of Cardiology
Volume 99, Issue 9 , Pages 1212-1215 , 1 May 2007

Article Tools